Topic

Michael Wong is an emeritus board member of the Harvard Business School Healthcare Alumni Association (HBSHAA).

Articles

Author Deepa Purushothaman discusses the progress of women and women of color in corporate America.

Has the Glass Ceiling Finally Been Broken at the Big Four Consulting Firms?

Pete O'Heeron, founder, chairman, and CEO of FibroBiologics, explains the key principles that biotechnology companies should follow.

Governing Principles for Successful Biotechnology Companies

Michael Ku, VP of global clinical supply at Pfizer, shares insights for the c-suite as well as reveals behind-the-scenes insight into Pfizer’s ability to deliver a COVID-19 vaccine swiftly.

How Pfizer Delivered the COVID-19 Vaccine in Record Time

Peter A. Vaccaro is the market access strategist for Formulary Insights.

A clearer understanding of the Inflation Reduction Act’s implications is needed for manufacturers to plot a successful course forward.

Biopharma Leaders Prepare to Navigate Medicare’s New Negotiating Power

Rocket Pharmaceutical's CEO and CTO spoke with Pharm Exec about adding a new position to the company's C-suite.

Q&A with Rocket Pharmaceutical's CTO Mayo Pujols and CEO Gaurav Shah

Life sciences companies are collaborating more with technology enterprises, universities, and other groups, which is changing the landscape of the industry.

As the Life Sciences Industry Transforms, New Risks Emerge

Barnes discusses alternative reimbursement plans for expensive, one-off therapies.

Q&A With Kim Barnes, Executive Vice President at Phacilitate

How pharma companies can make sure their corporate strategy in ESG is appealing to younger generations—and aligns with the issues this large segment of sustainability investors care about most.

Elevating ESG Message: Today’s Modern Investor is Key

Corrigan discusses the importance of a patient-centric approach.

Q&A With ConnectiveRx CEO Jim Corrigan

VP, late development, immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson.

Patients with Crohn's disease and ulcerative colitis face a high disease burden.

Strategy